Mediastinal extravasation of oxaliplatin.
Department of Medical Oncology, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain. cpericay@gmail.com
Carles Pericay
CP
Pijaume
Eugeni
E
Saigí
D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D062905:Central Venous Catheters; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005119:Extravasation of Diagnostic and Therapeutic Materials; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007049:Iatrogenic Disease; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008480:Mediastinitis / Q000139:chemically induced*; D008482:Mediastinum; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil